Introduction
Negative dromotropic effect is an important therapeutic goal in the majority of patients with supraventricular tachyarrhythmias. In patients with paroxysmal supraventricular tachycardias pharmacological inhibition of AV-nodal conduction is the main modality for acute termination of the reentry cycle if the AV-node is part of the reentry. Long term inhibition of AV-nodal conduction may also be used as a bridging modality or an alternative for ablation therapy (Blomstrom-Lundqvist et al., 2003) . In patients with atrial fibrillation (AF) or atrial flutter\tachycadia prolongation of AV-nodal refractoriness is the main strategy to control ventricular response rate. Moreover, since current anti-arrhythmic modalities are ineffective in a large proportion of AF patients, proper long term control of ventricular response rate is critical for symptomatic relief, improvement of hemodynamic status and prevention of tachycardiainduced cardiomyopathy (Reviewed in (Gopinathannair et al., 2009) ).
In many clinical instances, selective and potent negative dromotropic effect may be highly desirable during supravetricular tachyarrhythmias. This is specifically true for situations of acute reversible stress, like recent myocardial infarction, the post-thoracic surgery setting, sepsis and various other acute conditions in the emergency room\intensive care environment. However, current pharmacological approaches to achieve negative dromotropic effect are limited and nonselective: Digitalis acts rather slowly and is not effective in the face of the vagal withdrawal that often characterizes acute stress situation. β -Adrenergic receptor blockers are often ineffective in acutely stressful situations and can have undesirable adverse effects on ventricular contractility and bronchial smooth muscle tone. Ca
2+
-channel blockers can impair ventricular contractility and can cause hypotension, and their pharmacokinetics make sustained safe and effective doses difficult to achieve by intravenous administration (Fuster et al., 2006) . Adenosine, an endogenous nucleoside which activates several cell-surface receptor subtypes (Jacobson and Gao, 2006) , is a potent inhibitor of AV-nodal conduction. This beneficial effect of adenosine is mediated by activation of A 1 receptor (A 1 R), which also causes slowing of sinus rate, depression of atrial, but not ventricular contractility and attenuation of the stimulatory effects of catecholamines on the myocardium (Belardinelli and Lerman, 1990 ; Shryock and Belardinelli, 1997) . The AV-nodal effects of adenosine are related to the opening of G iβγ -coupled K + -channels as well as to a depression of I Ca,L (Wang et al., 1996) . As a result, adenosine causes rate-dependent impairment of AV nodal function that results in substantial and effective block at rapid rates (Nayebpour et al., 1993; Lai et al., 1994) . Nevertheless, the therapeutic utility of adenosine is limited to the acute treatment of AV-nodal dependent PSVT owing to its extremely short physiological half-life and its hemodynamic side-effects, which are mainly related to the activation of A 2A receptors (Wilbur and Marchlinski, 1997) . Selective activation of A 1 R is considered as a promising new approach to achieve potent slowing of AV-nodal conduction without decreasing cardiac contractility. N-(3(R)-tetrahydrofuranyl)-6-aminopurine riboside (CVT-510), a pharmacological agent designed for this purpose, was found to have selective negative dromotropic effect in the Guinea-pig heart when compared to diltiazem (Snowdy et al., 1999) . Moreover, phase I-II clinical studies have also shown promising results with relatively low side effect profile in the setting of PSVT (Reviewed in (Cheung and Lerman, 2003) ) and a possible benefit for acute rate control in patients with AF.
INO-8875 is a potent (Ki = 0.97 nM) and selective (> 10,000-fold versus A 2A ) A1R agonist (Etzion et al., 2008b; Kim et al., 2009 ) the structure of which is shown in Supplemental Figure 1 according to its publication in PCT/EP2011/064829 (Kalar et al. 2012 
Isolated perfused heart preparation
Experiments were conducted on hearts of adult male rats (250-350 g). Following intraperitoneal (IP) injection of heparin (500 units/kg) each rat was anesthetized with IP injection of ketamine/xylazine (75/5 mg/Kg) and the heart was isolated from the chest. The aorta was This article has not been copyedited and formatted. The final version may differ from this version. 
Anesthetized rat preparation
This article has not been copyedited and formatted. The final version may differ from this version. (Etzion et al., 2008a) . Positive-end expiratory pressure of 3 cm H 2 O was applied continuously and increased to 5 cm H 2 O upon thoracotomy (see below). Maintenance of anesthesia was applied with 2.5 % isoflurane. Body temperature was continuously monitored with a rectal thermometer and was maintained at 37°C by a heating pad. IV line was inserted in the tail vain and saline injection at a rate of 1 ml/hour was constantly applied using a syringe pump. The animals were connected to an electrophysiological system (Nihon Kodhen), and Surface ECG was monitored using cutaneous clips fixed on each limb.
Electrophysiological recordings: EP recordings were done as previously described (Etzion et al., 2008a) . Briefly, through a Rt. lateral thoracotomy, two pairs of mini-bipolar hook electrodes were inserted on the upper and lower lateral aspects of the right atrium. The upper electrode was used for stimulation and the lower for recording of the atrial activity. A third bipolar electrode was inserted on the right ventricle for assessment of the ventricular response.
Electrophysiological signals were interfaced with a PC using a conventional A/D converter board (National Instruments). Electrical stimulation consisted of square current pulses of 2 ms duration applied through an isolation unit (Iso-Flex, AMPI). EP protocols included basal recordings of RR interval, PR interval and QT interval (if easily detected in the ECG). Thereafter, programmed S1-S2 stimulation protocol (in 1 ms steps) was used to determine the AV node refractory-period (AVERP) and the atrial effective refractory-period (AERP). A decremental atrial pacing protocol starting from 150 ms cycle length (CL) down to 20 ms CL (in 5 ms steps) was thereafter used.
Each step consisted of a 5 S long train of 2 ms pulses. This protocol was used to determine the
AV-nodal Wenckebach conduction block (AV-Wenck).
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Statistical analysis
Values are expressed as means ± SE. Student's t-test or 1-way ANOVA was used as required (SigmaStat 3.1, Systat Software, Inc, Point Richmond, CA). Statistical significance was set at p < 0.05. In all figures, * signifies p < 0.05 and ** p < 0.01.
Results

Effects of INO-8875 in the isolated rat heart
As a first step in characterizing the cardiovascular profile of INO-8875, the concentrationdependence effect of the drug was evaluated in isolated perfused rat heart (n=5). In these experiments continuous atrial pacing (150 ms cycle length) was employed and the coronary flow was maintained at 10 ml/min. Under these conditions, the hearts were exposed to increased concentrations of INO-8875 (0.5 nM up to 3000 nM). 
Effect of INO-8875 on arterial blood pressure in anesthetized rats
To further evaluate the hemodynamic profile of INO-8875, arterial blood pressure measurements were applied in anesthetized rats and INO-8875 was applied up to a cumulative dose of 100 μg/Kg. A 1 R activation in rodents is known to potently affect SA node function, leading to reduced heart rates (Froldi and Belardinelli, 1990) . Therefore, constant atrial pacing (150 ms CL) was applied in these experiments in order to evaluate the 
Electrophysiological effects of INO-8875 and CVT-510 in anesthetized rats
In vivo evaluation of supraventricular EP in small animals is a challenging task and therefore most data on the EP effects of adenosine receptor agonists currently comes from ex vivo and in vitro experiments in these species (Froldi and Belardinelli, 1990; Snowdy et al., 1999; Song et al., 2002) . We recently demonstrated that utilizing an array of bipolar mini-hook electrodes implanted through small lateral thoracotomy, evaluation of the supraventricular EP of rodents can be consistently obtained (Etzion et al., 2008a) . In the present study we utilized this new setup to explore in detail the EP effects of INO-8875 Since the EP effects of the A 1 R agonist CVT-510 were previously studied in detail in the guinea-pig isolated heart as well as in human subjects (Reviewed in (Cheung and Lerman, 2003) figure 5B ). In addition, when % increase in AV-Wenck / % increase in RR were calculated for all animals exposed to equivalent doses of both drugs ( Figure 5C slowing at a concentration of 100nM whereas coronary conductance and LV function were not affected up to a 30 fold higher concentration (3000nM, the maximal tested in the present study). Although some concern may be noted regarding the difference in species that were used to evaluate this point (rats in the present study for INO-8875 vs. guinea-pigs in Snowdy et al. 1999 for CVT-510), it is worth noting that in a previous report (Ueeda et al., 1991) , the sensitivities of the AV-node and the coronary vasculature were directly compared in rats vs. guinea pigs using wide variety of selective and non-selective adenosine receptor agonists. The results of this study indicated an approximately 7 fold higher sensitivity of the guinea-pig AV-node compared to the rat, whereas coronary vasodilation was only 2 fold more sensitive in the guinea-pig. Therefore, it seems unlikely that a difference in species can account for the total absence of change in coronary conductance that was noted in the present study in a concentration up to 30 fold higher than the concentration which affected the AV-node. In terms of magnitude, the AV-nodal slowing effect of INO-8875 (~20% at 100 nM and 25% increase at higher doses) can be interpreted as potent considering the relative insensitivity of the rat AV-node to adenosine (Froldi and Belardinelli, 1990; Ueeda et al., 1991) . Indeed, the effect of 10-20 μM of adenosine on the rat AV-node could not reach 15% in the study of Froldi et al (1990) (see their Figure 2A ).
Moreover, since the noted results of Froldi et al. are based on S-H interval recordings while our data is based on S-V measurements, some underestimation of the actual effect on the AV-node is intrinsically inherited in our results. In conclusion, our isolated heart data are consistent with a functional activity of INO-8875 as a potent and highly selective A 1 R agonist.
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In vivo findings
Invasive blood pressure measurements, which were done in the presence of continuous atrial pacing are consistent with the isolated heart data and indicate a favorable hemodynamic profile of . Nevertheless, at the higher cumulative doses of the drug (75μg/Kg and 100 μg/Kg, Figure 2 ) a mild reduction in blood pressure was noted.
Based on the isolated heart data, which did not find any effect on cardiac contractility at concentrations up to 30 fold higher then those causing a dromotropic effect, it is reasonable to speculate that this in vivo effect of INO-8875 may not be related to a direct effect on cardiac function.
The cardiac effects of adenosine are highly species-dependent (Froldi and Belardinelli, 1990) . In rats the typical supraventricular effects of A 1 R activation include a potent negative chronotropic effect as well as milder effects on AV-nodal conduction and atrial Statistical significance was determined using 1-way ANOVA of repeated measures. This article has not been copyedited and formatted. The final version may differ from this version.
